U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaf

Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 186.0% to $3.58 during Wednesda

U.S. stocks rose; Apogee surged 10% on strong results and raised guidance, while Option Care, Ginkgo

-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clin

Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology firm developing one-time curative genetic therap

The FDA clears Prime Medicine’s IND application for PM647, an investigational in vivo Prime Editor f

INLIF shares jumped 78% after H1 FY26 revenue rose 26%, gross profit surged 159% and net income turn

Scholastic fell on weak results, Costco beat estimates, Prime Medicine gained on FDA clearance, and

Gainers Prime Medicine (NASDAQ:PRME) shares increased by 13.0% to $3.47 during Thursday's after

-- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver f

-- Clearance highlights continued execution, modularity and momentum across Prime Medicine's liver f

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Tran

MONTREAL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Co

CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechn

BlackRock Inc. acquired a new stake in shares of Prime Medicine, Inc. (NASDAQ: PRME) in the undefine

Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str

BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outp

Prime Medicine trades at a $548M valuation, significantly undervaluing its broad, potentially best-i

HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.24 per share in line with the Zacks

Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.24) per share which beat the analyst c

Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a l

-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/

-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/

Amova Asset Management Americas Inc. lessened its position in Prime Medicine, Inc. (NASDAQ: PRME) by

Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing cont

Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dis

Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its A

U.S. stocks fell, Nasdaq down 100 points. Penguin Solutions Inc (PENG) rose 18.8% after better-than-

-- Arbitration tribunal declared that PM647 is within Prime Medicine’s "Field", confirming P

-- Arbitration tribunal declared that PM647 is within Prime Medicine's “Field”, confirming Prime Med

Dow Jones gains 350 points, Iridium acquired by Rocket Lab for $8B, big stocks recording gains: Quid

Top Wall Street analysts upgraded Prime Medicine, Inc and Casey's General Stores Inc, and upgrad

HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ:PRME) from Neutral to B

-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published

-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published

Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of

-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577

Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead

Prime Medicine's PM359 data gives the stock some early human validation for its main value driver: P

MONTREAL, June 12, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Com

Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries,

Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.28) per share which missed the analyst

Oppenheimer analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ:PRME) with a Ou

LifeSci Capital initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and an

Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of d

Citigroup analyst Samantha Semenkow maintains Prime Medicine (NASDAQ:PRME) with a Neutral and low

Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and low